香港醫思醫療集團(02138.HK)擬配售最多2963.6萬股 淨籌2.3億港元
格隆匯 4 月 19日丨香港醫思醫療集團(02138.HK)發佈公吿,2021年4月16日,公司與配售代理(即海通國際)訂立配售協議,據此,公司有條件同意透過配售代理按盡力基準以每股配售股份7.80港元的價格向承配人配售最多合共2963.6萬股配售股份。
預期配售股份將配售予鄭志剛(以個人名義投資)及Aspex Master Fund。承配人(即鄭志剛)為一名文化企業家及一名個人投資者,而Aspex為一間於開曼羣島註冊成立的獲豁免有限公司,以私人投資基金形式營運。Aspex Management (HK) Limited為一間於香港成立的持牌法團,可根據證券及期貨條例於香港從事第9類(資產管理)受規管活動,並擔任Aspex的投資經理。
可予配發及發行的配售股份將動用一般授權,並將佔公司於本公吿日期現有已發行股本的2.77%及經擴大已發行股本的約2.69%。配售價每股7.80港元較4月16日(即配售協議日期)在聯交所所報的收市價每股股份7.68港元溢價約1.56%。
假設配售代理成功配售所有配售股份,配售事項的估計所得款項總額及所得款項淨額將分別約為2.312億港元及2.31億港元。淨配售價估計約為每股配售股份7.79港元。公司擬將配售事項所得款項淨額用於擴大集團於中國香港及中國大灣區的診所網絡、併購及集團的一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.